HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines.

Abstract
Recent data suggest that expression of the membrane P170-glycoprotein (P-gp) may confer resistance to the topoisomerase-I-interactive agent topotecan. The present study describes the cellular effects of a new dihydropyridine analogue, PAK-200S, on P-gp-mediated resistance to topotecan in human breast and ovarian tumour cells. PAK-200S at a non-cytotoxic concentration of 2.0 microM completely reversed resistance to topotecan in P-gp-expressing MCF-7/adr (breast) and A2780/Dx5 (ovarian) tumour cells, respectively, with no effects on parental cells. Cellular pharmacokinetic studies by reversed-phase high-performance liquid chromatography analysis showed significantly lower cellular drug concentrations of the pharmacologically active closed-ring lactone of topotecan in multidrug-resistant cells than in parental cells. PAK-200S was effective in restoring the cellular lactone concentrations of topotecan in resistant MCF-7/adr cells to levels comparable to those obtained in parental cells. Furthermore, exposure of MCF-7/adr cells to topotecan in the presence of PAK-200S significantly increased the induction of protein-linked DNA breaks. PAK-200S did not alter nuclear topoisomerase I-mediated ex vivo pBR322 DNA plasmid unwinding activity and topoisomerase-I protein expression. These results suggest that reversal of P-gp-mediated resistance to topotecan by PAK-200S was related to the restoration of cellular drug concentrations of the active lactone form of topotecan rather than a direct effect on topoisomerase-I function.
AuthorsU Vanhoefer, M R Müller, R A Hilger, B Lindtner, U Klaassen, N Schleucher, Y M Rustum, S Seeber, A Harstrick
JournalBritish journal of cancer (Br J Cancer) Vol. 81 Issue 8 Pg. 1304-10 (Dec 1999) ISSN: 0007-0920 [Print] England
PMID10604726 (Publication Type: Journal Article)
Chemical References
  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Antineoplastic Agents
  • Dihydropyridines
  • PAK 200
  • Topotecan
  • DNA Topoisomerases, Type I
  • DNA Topoisomerases, Type II
Topics
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 (genetics)
  • Antineoplastic Agents (pharmacokinetics, pharmacology)
  • Blotting, Western
  • DNA Topoisomerases, Type I (metabolism)
  • DNA Topoisomerases, Type II (metabolism)
  • Dihydropyridines (pharmacology)
  • Drug Resistance, Neoplasm (genetics)
  • Drug Screening Assays, Antitumor
  • Drug Synergism
  • Humans
  • Neoplasms (enzymology, genetics, pathology)
  • Phenotype
  • Topotecan (pharmacokinetics, pharmacology)
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: